Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. - Wikidata - awgldk - TriplyDB

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q37164915

about

The epigenetic basis of diffuse large B-cell lymphoma Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies Epigenetic roles in the malignant transformation of gastric mucosal cells Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.Inhibiting DNA Methylation by 5-Aza-2'-deoxycytidine ameliorates atherosclerosis through suppressing macrophage inflammation.6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.Chromatin Memory in the Development of Human Cancers Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphoma Sex affects bone morphogenetic protein type II receptor signaling in pulmonary artery smooth muscle cells.Epigenomic evolution in diffuse large B-cell lymphomas DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.Ex vivo engineered immune organoids for controlled germinal center reactions.Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.The Impact of DNA Methylation in Hematopoietic Malignancies.Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma.Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Genetic and molecular targets in lymphoma: implications for prognosis and treatment.Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies.Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells.Epigenetic dysregulation in follicular lymphoma.Epigenetics: A primer for clinicians.Epigenetic Determinants of Cancer.Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.DNA Methyltransferase Inhibitors: Development and Applications.Genetic background and evolution of relapses in aggressive B-cell lymphomas.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas

P2860

Q26852288-970A4262-D90D-421B-8E63-B89D819BB0A7 Q27304386-20FB7310-4502-4CF7-9C8C-2FFDEE611190 Q28067817-72AECACB-34C3-45B8-B388-4A6DD7BCD44E Q28070086-E0F0F308-6131-4279-9B06-52CF7374C927 Q34483455-ACF1A4F8-86CD-42D6-A3D6-48AB3B41A6A3 Q34551679-A4945F99-FDA1-42B5-B2AC-A5225047AEBC Q34748281-436948FA-452B-487A-8388-8155B3394221 Q34979975-34AD9628-6272-4217-8391-BAEAFA287BD3 Q35138335-9F13A083-9014-4017-AE9C-C0E551E21EDE Q35262038-01A37FC6-9F04-4EA1-9B81-93A44C98DC08 Q35543203-682DE5CA-6522-4A44-9519-EBE14C261850 Q35568457-4839689E-74B8-4CDF-867A-135FC32B1A27 Q35695410-B01886F0-3D5C-45C4-9D64-9E4D3E05D8AE Q35812007-934E2E97-A3C3-48F7-BD17-2AFDA631AD70 Q36020841-7D804001-E711-4EBC-9852-EC6FEB1ACA4B Q36724810-9C5317C2-4FCA-429F-B6EB-9232AE01E323 Q36871785-9625E9F7-34DC-4D18-BE5E-C15286C2F809 Q37117964-C61F3CFD-04BB-4CB5-AB78-B2D0AAE89D9C Q37240290-A14F33E5-C3F1-4BB5-B2BB-B9D96B521413 Q37290684-80D851C4-4C2E-4A64-8597-C60A68A65025 Q37594238-AD8337BE-06AF-4671-A230-B6A9910B63A0 Q38214120-5E321D66-350E-43A3-A49A-B62D98496CBF Q38240579-9B35269A-7796-432B-80A4-EBFDF126A054 Q38294626-960076F0-E623-4800-9918-198F45E196D4 Q38459887-3BCDF009-0F8C-4982-BF9D-50BD5C82A0F0 Q38504989-FA2AE90F-ECA5-4E1B-AC20-8B776EEB7E34 Q38542620-563A89DF-4206-4B32-8001-767C7B74EEFE Q38664822-0B0AC43A-AEE3-41C0-B5D8-C16BCEECAD01 Q38668222-D3BC6853-89DF-4FE2-9499-2FB23204122F Q38677466-0F231482-7697-419C-9D4C-E9C237F55DED Q38770916-1054BF11-C327-44DA-84D8-2A2D6244467C Q38837858-6271D957-900C-444F-9462-6B94C103E411 Q38882112-87B6AAD6-3EAA-42B9-AFF0-E7B5B76A93AF Q38918235-62CAA944-FDCE-4C0B-BBCF-2A43DEA3BE03 Q38962085-3E405785-9F98-4020-B646-8FE4911DB1BA Q39003558-36FF2D37-DBF8-46B6-945D-BE502EF8BF26 Q39336821-77160003-BFF5-48F9-B2CD-418E6AF08096 Q39381251-F98DAEBA-ACAA-44E0-83EA-E8DB2D848A33 Q39520264-FE2E64F7-F8A2-4F92-8AEB-22F76F564E49 Q40974570-D2FC7E9F-F265-4992-8016-EF5D41142744

P2860

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q37164915

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@en

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@nl

type

label

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@en

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@nl

prefLabel

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@en

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@nl

P1433

Q37164915-8045380B-9729-4BCF-BF8E-495D8C803418

P1476

Q37164915-470EBA22-909D-432F-8BD6-2D674195D5AC

P2093

Q37164915-0CB787E0-2BFA-4067-A33B-BD6E93190981

Q37164915-0E8CF2CF-0F42-402B-81B7-6B24D2E1D7AC

Q37164915-2842C09C-B3EA-4E01-A417-D215D338D853

Q37164915-2A057E10-9DCE-4F03-B071-1072A62D2F06

Q37164915-2EC588FD-4F0A-43E9-B3E9-3058F025FB8F

Q37164915-4F912DF9-F753-4EBA-896D-B8117C2A7559

Q37164915-618CF4B2-EDE2-451B-9A51-8F3B095FA445

Q37164915-731B15BE-B753-43D4-B62D-AE75181B9F9D

Q37164915-79E58598-7523-4ED1-884B-698AE3015476

Q37164915-87F065FB-C919-4759-9BFA-92234791A83B

P2860

Q37164915-02988484-DB5F-485B-B2A6-069C70A0999C

Q37164915-0513CCA3-D15C-4294-B909-46DF7F4D8FA9

Q37164915-07385734-F7AB-450C-BF58-1ADC6970D3B0

Q37164915-0A6BA56E-B947-44C7-8993-BAD598D32224

Q37164915-0FD2CAB6-2726-4DC6-AFD9-D8910525EEF7

Q37164915-1488E42D-D504-42F8-BB30-C56F7426FA1F

Q37164915-185FDC77-EC08-4CCF-8453-E5430749AAEB

Q37164915-1A03EE94-0D13-4E7C-95F7-D6BB44D38EAE

Q37164915-1B6ABFF8-6855-4B41-95FE-332B64809954

Q37164915-1F5F51A7-62BF-42BC-A138-46EC04B5D081

P304

Q37164915-5A6689AD-0882-4257-91B3-C1CE21995DA6

P31

Q37164915-DE0A31E7-5B8A-4C3C-BC7D-7288791DDE82

P356

Q37164915-748E1FF9-9055-415E-AF24-FBC1221603EB

P433

Q37164915-1DA8D257-CA0B-4C87-A678-A113AA80FF65

P478

Q37164915-19231424-65F0-4583-92ED-1268B8E3A9A3

P50

Q37164915-208AE3F5-9D17-462B-A8EE-AEAA67E18DA1

Q37164915-8EAEBDFB-BBB2-4793-9C54-7BFA12AF4319

Q37164915-AFFA20DC-D953-43DC-9785-DD2DBD3F6641

Q37164915-DF1186CD-A9C2-41F5-9414-DFDAD7369DC3

P577

Q37164915-4DB30C3C-76C6-4BCD-8404-7B62E342A3E0

P5875

Q37164915-6325E5B9-3C3A-47CC-91C2-09D65DD5CE8C

P698

Q37164915-AADCE73B-549B-4A8F-9192-F18886DFEBC8

P921

Q37164915-A87FDBAE-3A6C-4BF9-9876-13A719912C9F

P932

Q37164915-5819C20D-85A9-45DD-A2FA-76871CA69ECE

P356

2159-8290.CD-13-0117

P1433

Cancer Discovery

P1476

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

@en

P2093

Amy Chadburn

http://www.w3.org/2001/XMLSchema#string

Aparna Vasanthakumar

http://www.w3.org/2001/XMLSchema#string

Ari Melnick

http://www.w3.org/2001/XMLSchema#string

Biljana Culjkovic

http://www.w3.org/2001/XMLSchema#string

David W Scott

http://www.w3.org/2001/XMLSchema#string

Fabrizio Tabbo

http://www.w3.org/2001/XMLSchema#string

Giorgio Inghirami

http://www.w3.org/2001/XMLSchema#string

John P Leonard

http://www.w3.org/2001/XMLSchema#string

Katherine L Borden

http://www.w3.org/2001/XMLSchema#string

Lucy A Godley

http://www.w3.org/2001/XMLSchema#string

P2860

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis

Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts

The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores

Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Stromal gene signatures in large-B-cell lymphomas

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Targeting epigenetic changes in acute myeloid leukemia.

P304

1002-1019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-0117

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Leandro Cerchietti

Giorgio Inghirami

Randy D Gascoyne

P577

2013-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255975113

http://www.w3.org/2001/XMLSchema#string

P698

23955273

http://www.w3.org/2001/XMLSchema#string

P921

P932

3770813

http://www.w3.org/2001/XMLSchema#string